flt3
No description yet: the sentence for this tag has not been written. 4 records carry it: 2 people, 2 biomarkers.
By kind
4 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Alexander E. Perl Professor of Medicine, Abramson Cancer Center, University of Pennsylvania · Abramson Cancer Center, University of Pennsylvania Led ADMIRAL, which made gilteritinib the standard for relapsed FLT3-mutant AML. | Acute myeloid leukaemia | none | aml, targeted-therapy | ||
FLT3-ITD (internal tandem duplication) FLT3 FLT3-ITD is a duplicated stretch of the FLT3 receptor gene found in about a quarter of acute myeloid leukaemias; it makes relapse more likely and is treated with midostaurin, quizartinib or gilteritinib. | Acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia | none | biomarker | ||
FLT3-TKD (D835 and I836 tyrosine kinase domain mutations) FLT3 FLT3-TKD mutations are point changes in the kinase's activation loop, found in about 7 percent of acute myeloid leukaemias. Midostaurin and gilteritinib labels cover them; quizartinib's does not. | Acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia | none | biomarker | ||
Richard M. Stone Chief of Staff and Director of Translational Research, Adult Leukemia Program, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Led RATIFY, the trial that made midostaurin the first targeted therapy added to induction chemotherapy for AML. | Acute myeloid leukaemia | none | aml, cooperative-group |
